Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intel

York Water

These rock-solid companies check all the right boxes for investors who want steady wealth creation with minimal volatility.

3 Exceptionally Low-Risk Stocks That Can Turn $400,000 Into $1 Million by 2030

Walgreens Boots Alliance Appoints Bryan C. Hanson to Board of Directors

The stock offers an abnormally high payout, but investors will want to take the company's outlook into consideration as well.

Is Walgreens' 5.4% Dividend Yield Safe?

Salesforce

Home Depot

These blue chip stocks look like attractive investments after large declines this year.

Buy the Dip on These 3 Dow Stocks Down Over 30% in 2022

CVS Health

Their business models seem similar, but their stock performances have diverged quite a bit.

Better Growth Stock: Walgreens Boots Alliance vs. CVS Health

Walgreens Boots Alliance to Participate in Credit Suisse 31st Annual Healthcare Conference

AGNC Investment

Enbridge

CBRE Global Real Estate Income Fund

Kinder Morgan

AT&T

Verizon

Exxon Mobil

The Dividend Harvesting Portfolio is now generating $630.84 in annual dividends yielding 8.05%. The Dividend Harvesting portfolio has an 81.40% record of finishing the week in the black since its inception, 70/86 weeks.

Dividend Harvesting Week 86 Update: $8,600 Allocated, $630.84 In Annual Dividends

T. Rowe Price Group

Western Union

As market volatility continues on the back of a disappointing start to tech companies' earnings, rising interest rates and rampant inflation, many investors are looking for some stability in their portfolios.

5 Historically High-Yield Stocks Popular With Gurus

Abbott Labs

Albemarle

Clorox

Ecolab

Lowe's

Medtronic

McCormick

Nucor

Realty Income Corp

Sherwin-Williams

Stanley Black & Decker

Sysco

Target

V.F.

West Pharmaceutical Services

NOBL fell 9.15% in September, which brings the Funds return for the year to a loss of 17.47%. Thus far this month, through October 24th, the dividend aristocrat ETF is up 6.04%, bringing its year-to-date return to -12.49%.

My Best Dividend Aristocrats For November 2022

Walgreens Sharpens Focus on Patient Care and Experience, Eliminating Task-Based Metrics for Pharmacy Staff Performance Reviews Chainwide

These companies offer big-time dividend yields.

3 Big-Time Passive Income Stocks to Consider Loading Up On During the Bear Market

Walgreens Flu Index Shows Flu Activity Trending 10 Times Higher Year Over Year

Blue Apron

Gold Fields Ltd.

As we start to think about wrapping up 2022, looking to next year and thinking about what the market will provide is exciting. Indeed, this year has been one in which simplifying and de-risking portfolios has been a profitable task.

3 Stocks to Sell That Will Be Big Losers in 2023

The federal government launched a probe into whether the nation's largest drug store chains -- including Walgreens and CVS -- have refused to dispense meds that can induce abortions after Roe v. Wade was overturned.

Walgreens, CVS probed by feds over denial of meds after Roe overturned

Rite Aid

The Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain from the growing demand for digital healthcare support. However, reimbursement challenges are hurting overall industry health.

3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Challenges

Medical Properties Trust

National Retail Properties

New York Community Bancorp

Southern Company

The Dividend Harvesting Portfolio is now generating $622.75 in annual dividends yielding 8.25%. The Dividend Harvesting portfolio has an 82.35% record of finishing the week in the black since its inception, 70/85 weeks.

Dividend Harvesting Week 85 Update: $8,500 Allocated, $622.75 In Annual Dividends Yielding 8.25% Across 77 Positions

The billionaire investor doesn't pay much attention to economic forecasts.

Why Warren Buffett Buys Stocks in a Bear Market

PepsiCo

Despite facing economic headwinds, earnings for Walgreens and PepsiCo recently came in better than analyst expectations.

2 Stocks That Are Beating Expectations In the Bear Market

The state of New Mexico on Tuesday urged a judge to hold Walgreens Boots Alliance Inc responsible for fueling the opioid crisis in the state, delivering a closing argument in the latest of several trials around the country against the pharmacy chain.

New Mexico presses opioid case vs Walgreens after settling with Walmart, Kroger

Disney

Cisco Systems

Chevron

Dow Inc

Microsoft

On Thursday, Wedbush analyst Dan Ives reiterated his $215 target price for Salesforce (NYSE: CRM ), re-crowning the software firm as the Dow Jones stock with the highest implied upside. For many first-time investors, these target prices are often irresistible.

The 10 Best Dow Jones Stocks to Buy Before the Market Recovers

Equinix

Zscaler

These growth stocks are trading at much lower valuations these days.

Nasdaq Bear Market: 3 Unstoppable Growth Stocks Down 35%+ You'll Likely Regret Not Buying

The drugstore chain plans to use data analytics to win back consumers through personalized digital marketing.

Walgreens Chases Customers It Lost During Covid Focus

A recent initiative could mean a reversal of fortunes for this healthcare mainstay.

3 Things About Walgreens Boots Alliance That Smart Investors Know

Shares may be establishing a bottom as WBA has bounced off of the $30 lows and is trading at less than 15x its FCF. Walgreens is executing its turnaround plan, growing the U.S. business, and has a strong outlook over the next several years.

Walgreens: Shares May Be Establishing A Bottom After A Q4 Beat

Walgreens Boots Alliance is a company in transition. It had ventured into the local clinical care business. It had embarked on Cost Transformation Program whose benefits have yet to be fully realized. There is a strong operating track record to suggest that it would be successful in its transformation. It is also financially strong to give it time to realize the results.

Walgreens Boots Alliance - A Company In Transition

News for Walgreens Stock (WBA)